

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

Longitudinal protection following natural SARS-CoV-2 infection and early vaccine responses: insights from a cohort of community based dental health care professionals

Adrian M. Shields¹, Sian E. Faustini¹, Caroline A. Kristunas², Alex M. Cook³, Claire Backhouse¹, Lynsey Dunbar¹, Daniel Ebanks¹, Beena Emmanuel¹, Eddie Crouch⁴, Annika Kroeger^{5,6}, Josefine Hirschfeld^{5,7}, Praveen Sharma^{5,7}, Razza Jaffery⁵, Sylwia Nowak⁵, Samantha Gee⁵, Mark T. Drayson¹, Alex G. Richter¹, Thomas Dietrich^{5,6}, Iain C. Chapple^{5,7}

1. Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
2. Institute of Clinical Sciences, University of Birmingham, Birmingham, UK
3. The Binding Site Group Ltd, 8 Calthorpe Road, Birmingham, B15 1QT, UK.
4. Birmingham Local Dental Committee
5. Birmingham Community Healthcare Trust, Birmingham, UK
6. Department of Oral Surgery, The School of Dentistry, University of Birmingham, Birmingham, UK.
7. Periodontal Research Group, University of Birmingham.

Key words: Dentistry, SARS-CoV-2. COVID-19, vaccination, antibodies

Word count: 2,368

Number of figures: 1

Number of tables: 1

Correspondence to:

Prof Iain Chapple	-	i.i.c.chapple@bham.ac.uk
Prof Thomas Dietrich	-	t.dietrich@bham.ac.uk
Prof Alex Richter	-	a.g.richter@bham.ac.uk

38

39 **Abbreviations**

40

AGP	Aerosol generating procedures
COVID-19	Coronavirus disease 2019
DCP	Dental care professionals
GDP	General dental practitioners
IRM	International reference material
NIBSC	National Institute for Biological Standards and Control
PCR	Polymerase chain reaction
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
WHO	World Health Organization

41

42

43

44

45

46

47 **Abstract**

48

49 **Background**

50 The threshold of protection for anti-SARS-CoV-2 spike glycoprotein antibodies and their longevity are not
51 known. Interpretation of serological results in with respect to international reference material can inform
52 this essential question.

53

54 **Methods**

55 1,507 West Midlands dental care professionals were recruited into this study in June 2020. Baseline
56 seroprevalence of antibodies directed against the SARS-CoV-2 spike glycoprotein was determined and the
57 cohort was followed longitudinally for 6 months until January/February 2021 through the second wave of
58 the COVID-19 pandemic in the United Kingdom, and commencement of vaccination.

59

60 **Results**

61 Baseline seroprevalence was 16.3% in this cohort, compared to estimates in the general population of
62 between 6-7%. Seropositivity was retained in over 70% of participants at 3 and 6-month follow up and
63 conferred a 74% reduced risk of infection. During follow-up, no PCR-proven infections occurred in
64 individuals with a baseline anti-SARS-CoV-2 IgG level greater than 147.6 IU/ml with respect to the World
65 Health Organization international standard 20-136. Post-vaccination, antibody responses were more rapid
66 and of higher magnitude in individuals with who were seropositive at baseline.

67

68 **Conclusion**

69 Natural infection leads to a serological response that remains detectable in over 70% of individuals 6
70 months after initial sampling and 9 months from the peak of the first wave of the pandemic. This response
71 is associated with protection from future infection. Even if serological responses wane, a single dose of the
72 Pfizer-BioNTech vaccine is associated with an antibody response indicative of immunological memory.

73

74 **Funding**

75 The Association of Clinical Biochemistry and Laboratory Medicine and The Institute for Global Innovation
76 (IGI) of the University of Birmingham.

77

78 **Introduction**

79

80 Seroepidemiological studies of healthcare workers define occupational risk of exposure to the SARS-
81 CoV-2 virus [1-3] and seropositivity is associated with protection from subsequent infection in high-
82 exposure cohorts [4, 5]. Such studies have guided public health planning, the design of healthcare
83 services, and associated infection prevention protocols to mitigate risk and maintain essential care
84 services during the pandemic. However, an absolute level of antibodies that confers protection for a
85 given period of time remains unknown.

86 Dental care professionals (DCPs) represent a group of healthcare professionals thought to be at high-
87 risk of exposure to SARS-CoV-2 because they routinely operate within patients' aerodigestive tract and
88 undertake aerosol generating procedures (AGPs). The risks of occupational exposure to and infection
89 with SARS-CoV-2 in dental teams remains unclear despite studies evaluating aerosol generation and
90 viral recovery in relevant bodily fluids [6, 7]. Many dental practices across the world closed in March
91 2020 and, in the United Kingdom, did not re-open until June/July 2020, when level 3 personal protective
92 equipment (PPE) was in sufficient supply to enable resumption of AGPs for those in need of urgent
93 dental care. The impact of this policy on patients remains unclear.

94 In June 2020, we recruited a cohort of 1,507 community and hospital based DCPs from the West
95 Midlands region of the United Kingdom, following the first wave of the COVID-19 pandemic. The
96 longitudinal follow-up of this cohort through the second wave of the COVID-19 pandemic and following
97 the start of widespread vaccination of healthcare workers, afforded a unique opportunity to study
98 occupational risk factors in DCPs, the durability of serological responses and to compare the early
99 kinetics of serological responses following a single dose of the Pfizer-BioNTech vaccine based on prior
100 exposure to the virus. Furthermore, using World Health Organization (WHO) and National Institute for
101 Biological Standards and Control (NIBSC) international reference material, we were able to define an
102 anti-SARS-CoV-2 spike glycoprotein antibody concentration arising following natural infection
103 associated with protection from reinfection for 6 months.

104

105

106

107

108

109

110

111

112

113 **Methods**

114

115 Study recruitment

116 Registered general dental practitioners (GDPs) in the West Midlands area, were invited by email to
117 participate in a research study on SARS-CoV-2 antibody status in May 2020. GDPs were encouraged to
118 disseminate this invitation to their wider dental teams. A total of 1,716 individuals registered their interest,
119 of which 1,535 attended the first study visit and provided informed written consent. Twenty-three
120 individuals were excluded when they were found to not work in dentistry. 1,507 participants volunteered a
121 venous blood sample that was suitable for serological analysis at their first study appointment. Study
122 participants also provided occupational and ethnodemographic data. The index of multiple deprivation in
123 participants' home postcode were sourced from 2019 UK Ministry of Housing, Communities and Local
124 Government statistics [8]. Study data were collected and managed using REDCap electronic data capture
125 tools hosted at the University of Birmingham [9]. Individuals who were seropositive at baseline were
126 recalled three months later (September 2020) to study the persistence of their antibody response. All
127 participants were recalled six months after providing their baseline sample (January 2021). At the time of
128 manuscript preparation, 873 participants had volunteered a repeat blood sample suitable for serological
129 analysis.

130

131 Serological analysis

132 Serological analysis was performed using a commercially available, CE marked, IgGAM ELISA that
133 measures the total antibody response (IgG, IgA and IgM simultaneously) against the spike glycoprotein
134 (Product code: MK654, The Binding Site (TBS), Birmingham). Detailed descriptions of this assay including
135 its construction, validation and verification have been published previously [10, 11]. The assay is optimized
136 for seroepidemiological studies and demonstrates 98.3% (95% CI: 96.4-99.4%) specificity and 98.6%
137 sensitivity (95% CI: 92.6-100%) in detecting a serological response to the SARS-CoV-2 spike glycoprotein
138 following PCR-positive, non-hospitalised, mild-to-moderate COVID-19. Internal quality control material
139 demonstrates an inter-assay coefficient of variance of 7.2% at the cutoff. Samples are run at a standard
140 dilution of 1/40. To assess the response of individual immunoglobulin isotypes, the above protocol was
141 modified to employ polyclonal sheep-anti-human HRP-conjugated polyclonal antibodies against IgG
142 (1:16,000) and IgA (1:2000) as secondary antibodies. For these assays, a cutoff ratio of 1.0 relative to the
143 existing TBS cutoff calibrators was determined by plotting the pre-2019 negatives (n=90) in a frequency
144 histogram chart. Once the ratio cutoff was determined from the pre-2019 negatives, a cut-off multiplier of
145 1.0 and 0.71 was established for IgG and IgA respectively.

146

147 NIBSC and WHO standards

148 In late 2020, the National Institute for Biological Standards and Control (NIBSC) developed international
149 reference material (IRM) for the purposes of traceability and calibration of SARS-CoV-2 serological tests.
150 These include NIBSC 20/136, the first World Health Organization International Standard for anti-SARS-
151 CoV-2 immunoglobulin [12] and NIBSC 20/162. Serial dilutions of these IRM were run in triplicate on the
152 SARS-CoV-2 IgG assay described above. A receiver operator characteristics curve was constructed using
153 baseline anti-SARS-CoV-2 IgG antibody levels and binary seropositivity/seronegativity at 6 months as the
154 outcome variable. In reference to the NIBSC standard, the minimum level of anti-SARS-CoV-2 IgG
155 antibodies in baseline samples associated with protection for 6 months was inferred, based on the original
156 dilution of samples.

157

158

159

160 Statistical analysis

161 Data was analysed in Stata 16 (StataCorp. 2019. Stata Statistical Software: Release 16. College Station,
162 TX: StataCorp LLC.) and Graph Pad Prism 9.0 (GraphPad Prism Software, San Diego, California). With
163 respect to demographic data, categorical characteristics were compared using a Chi-Squared test and
164 continuous characteristics compared using the Wilcoxon Rank Sum Test. The distribution of IgG ratios at
165 different time points were compared using the Kolmogorov-Smirnov Test with a false discovery rate
166 approach set at 1% (Benjamini, Krieger and Yekutieli method).

167

168 Results

169

170 Following the first wave of the COVID-19 pandemic, the baseline seroprevalence of anti-SARS-CoV-2 spike
171 glycoprotein antibodies in this cohort of DCPs was 16.3% (n=246/1507) (**Table 1**). Ethnicity was a
172 significant risk factor for seropositivity at baseline, with higher seroprevalence observed in individuals of
173 Black ethnicity (35.0%), compared to those of Asian (18.8%) and white ethnicity (14.3%) (p=0.018). There
174 were no differences in seroprevalence between different DCPs; receptionists, who do not have direct
175 patient contact, had the lowest baseline seroprevalence (6.3%), a finding concordant with estimates of
176 seroprevalence in the general population of the West Midlands at the time of baseline sampling [13].
177 Current smoking was associated with a lower seroprevalence compared to never-smokers or ex-smokers
178 (7.6% vs 16.4% vs 17.6%, p=0.007). Deprivation was associated with a higher seroprevalence: the median
179 index of multiple deprivation rank was 8238 (IQR: 3240, 14408) for seropositive individuals compared to
180 12081 (IQR: 3858, 21795) for those that were seronegative (p=0.004).

181

182 The cohort was followed longitudinally: individuals who were seropositive at baseline were re-bled at 3
183 months to study the durability of serological responses (**Figure 1A**). 73% of individuals continued to have a
184 detectable serological response against the spike glycoprotein at three months and, in a subgroup of 79
185 individuals who were seropositive at baseline and who reattended prior to their vaccination at 6 months, a
186 serological response remained detectable in 72%. Individual IgG and IgA responses were also measured in
187 those who were seropositive. Anti-spike glycoprotein IgG and IgA response were detectable in 42% and
188 16% of individuals at baseline, reducing to 37% and 9% at 3 months respectively. The discordance between
189 seropositivity defined by the detection of the total antibody response (IgGAM) against the SARS-CoV-2
190 spike glycoprotein, compared to the IgG isotype, arises from the optimization of the assay for
191 seroepidemiological studies (see Methods).

192

193 61.4% (n=926/1507) of the cohort returned questionnaires regarding SARS-CoV-2 infections at 6 months
194 and 59.2% (n=873/1507) were re-bled. In this cohort, 77 PCR-positive SARS-CoV-2 infections were reported
195 by study participants, representing an overall infection risk of 8.3%. The risk of infection was 9.6% in
196 participants who were seronegative at baseline, compared to 2.8% in individuals who were seropositive
197 (p=0.001). As seropositivity at baseline in June 2020 could only be accounted for by SARS-CoV-2 infection,
198 these data suggest that the emergence of antibodies following natural infection with SARS-CoV-2 is
199 associated with a 74% risk reduction for future infection (Risk Ratio 0.26, 95% CI 0.11, 0.63, adjusted for
200 age, sex, ethnicity and smoking).

201

202 To further investigate, the phenomenon of re-infection in participants who were seropositive at baseline
203 using the IgGAM assay, participants' individual IgG and IgA responses against the SARS-CoV-2 spike
204 glycoprotein reviewed. Reinfections only occurred in the absence of a specific, detectable anti-spike
205 glycoprotein IgG response. Thus, to determine an absolute level of SARS-CoV-2 antibodies associated
206 with ongoing seropositivity at 6 months, we reviewed the baseline anti-spike glycoprotein IgG levels of the
207 79 participants who had been re-sampled prior to vaccination at 6 months (**Figure 1B**). An IgG ratio greater
208 than 2.97 conferred a likelihood ratio of 2.43 of IgG seropositivity at 6 months (sensitivity 69.7% CI 56.7-
209 80.1%, specificity 71.4% CI 35.9-94.2%); no participant with a baseline IgG ratio greater than 3.36 was IgG
210 seronegative at 6 months (sensitivity 60.7%, CI 47.6-72.4%, specificity 57.0-100.0%). In reference to the
211 first WHO standard for SARS-CoV-2 immunoglobulin (NIBSC 20/136) and the original dilution of the

212 baseline samples, we estimate that the minimum level of anti-SARS-CoV-2 spike glycoprotein IgG
213 antibodies necessary to confer 6 months protection from infection is 147.6 IU/ml (**Figure 1C**). Studies using
214 the NIBSC standard 20/162, generated a similar estimate of 195.2 U/ml.

215

216 873 participants were re-bled in January 2021 following 6 months of follow-up. Through natural infection
217 and vaccination, the overall seroprevalence had risen to 49.1% (n=429/873). In individuals who donated
218 serum prior to vaccination and who were seronegative at baseline (n=308), 36 PCR-positive infections
219 occurred and a further 24 asymptomatic seroconversion events had occurred, suggesting the infection risk
220 during the 6-month follow-up period may be as high as 19.4% (n=60/308). 51.5% (n=450/873) had received
221 a single dose of a SARS-CoV-2 vaccine (Oxford/AstraZeneca, n =17; Pfizer-BioNTech, n= 429; Unknown,
222 n=4). The serological responses of individuals receiving a single dose of the Pfizer-BioNTech SARS-CoV-2
223 were analysed based on prior exposure to the virus - defined by either positive baseline serology, or PCR-
224 proven infection during the follow up period (**Figure 1D**). Vaccination on the background of prior exposure
225 to the virus was associated with a more rapid and quantitatively greater total antibody response against
226 the SARS-CoV-2 spike glycoprotein, consistent with the boosting of immunological memory. In naive
227 participants, greater than 95% seroprevalence was achieved 12 days after vaccination.

228

229

230

231

232

233

234

235 Discussion

236

237 Consistent with other studies, we demonstrate that natural infection with SARS-CoV-2 is generally
238 associated with robust and durable serological responses [14, 15]. The percentage of individuals who lose
239 detectable serological responses after 3 months (30%) is higher than that reported in other studies. This is
240 most likely due to the sensitivity of the screening assay that measures the total antibody against the spike
241 glycoprotein [10]. This approach identifies individuals who are exposed to the virus with high sensitivity
242 but some individual appear to mount modest serological responses that are not associated with durable
243 immunity. Nevertheless, in this community based cohort, we corroborate the findings of Lumley et al [5]
244 and Hanrath et al [4] in demonstrating that seropositivity at baseline is associated with protection from
245 infection with SARS-CoV-2. We observed that symptomatic reinfections only occurred in individuals who
246 lacked a robust IgG response, and thus, by relating initial anti-spike glycoprotein IgG levels to the WHO
247 first international reference material for anti-SARS-CoV-2 immunoglobulin (NIBSC 20/136), define a
248 putative antibody level of 147.6 IU/ml that affords a minimum of 6 months protection from reinfection.
249 Clinically, real-world data that relate protection from infection with antibody binding in an *in vitro* assay is
250 invaluable. Further longitudinal studies in cohorts of individuals following natural infection and vaccination
251 will be necessary to replicate these findings with using assays that employ alternative target SARS-CoV-2
252 antigens, such as the receptor binding domain, or nucleocapsid.

253

254 Vaccination is the most cost-effective and efficacious public health intervention of modern times. In the
255 United Kingdom, the rapid deployment of the Pfizer-BioNTech SARS-CoV-2 vaccination coincided with a
256 planned 6-month follow up of this cohort, affording a unique opportunity to investigate the early
257 serological response to vaccination. Following a single dose of vaccine in naïve recipients, SARS-CoV-2
258 antibodies were detectable in over 95% of individuals 12 days after vaccination and persisted beyond 25
259 days post vaccination. In keeping with other contemporaneous studies, we also demonstrate that prior
260 viral infection leads to a more rapid and robust antibody response, consistent secondary immunological
261 responses [16, 17]. The nature and duration of immunity in these cohorts will be critical to understand as
262 the COVID-19 pandemic progresses, particularly with respect to the efficacy of vaccination strategies
263 (single-dose, multiple-doses, vaccine combinations) and in relation to novel viral variants of concern.

264

265 Finally, in this community-based cohort of over 1500 individuals, we demonstrate that DCP have a
266 significant occupational risk of exposure to the SARS-CoV-2 virus. The overall baseline seroprevalence in
267 this study of 16.3% exceeds that of the general population in the West Midlands region (6-7%) in June 2020
268 [13]. The observation that the seroprevalence amongst dental practice receptionists, who have no direct
269 patient contact, was comparable to the general population, supports the hypothesis that occupational risk
270 arose from close exposure to patients. Seroprevalence across the West Midlands region increased by
271 12.3% between June 2020 and January 2021 [18]; the risk of PCR-proven infection in seronegative DCPs in
272 our study during this time was 11.7%. Further studies are necessary to comprehensively understand
273 whether these comparative statistics represent a lowering of exposure rates of DCPs to background
274 population levels following reopening of general dental practices and the additional precautions taken to
275 ensure practices became COVID-19 secure.

276

277

278

279

280 **Figure Legends**

281

282 **Figure 1: A** Total anti-SARS-CoV-2 spike glycoprotein antibodies (Total GAM) and IgG and IgA anti SARS-
283 CoV-2 spike glycoprotein antibodies measured at baseline, 3 months and 6 month follow up. At 6 months,
284 only individuals who had not been vaccinated are shown. Data are provided as a ratio of the level of
285 antibody compared to the cutoff calibrator set at 1.0. Percentage of individual above the assay cutoff at
286 each time point is also provided above each column. Median and 95% confidence intervals are shown. **B**
287 Receiver operator characteristic curve describing the relationship between baseline anti SARS-CoV-2 spike
288 glycoprotein IgG ratio and binary IgG seropositivity at 6-month follow up. AUC = 0.80, $p=0.01$. **C**
289 International reference materials NIBSC 20-136 (WHO) and 20-162 was run in triplicate serial dilutions and
290 the IgG ratio determined. The minimum IgG ratio associated with guaranteed seropositivity 6 months
291 from baseline is shown by the red and blue dotted lines. **D** Kinetics of total antibody response in 423
292 individuals following a single dose of the Pfizer-BioNTech vaccine. * demonstrate a significant difference
293 ($p<0.05$) between the distributions of IgGAM ratios at each timepoint following vaccination between
294 individuals who were seropositives and seronegative at baseline as determined by Kolmogorov-Smirnov
295 test. Percentage of individual above the assay cutoff at each time point is also provided.

296

297

298

299 **References**

- 300 1. Eyre, D.W., et al., Differential occupational risks to healthcare workers from SARS-CoV-2 observed
301 during a prospective observational study. *Elife*, 2020. **9**.
- 302 2. Houlihan, C.F., et al., Pandemic peak SARS-CoV-2 infection and seroconversion rates in London
303 frontline health-care workers. *Lancet*, 2020. **396**(10246): p. e6-e7.
- 304 3. Shields, A., et al., SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a
305 cross-sectional study. *Thorax*, 2020.
- 306 4. Hanrath, A.T., B.A.I. Payne, and C.J.A. Duncan, Prior SARS-CoV-2 infection is associated with protection
307 against symptomatic reinfection. *J Infect*, 2020.
- 308 5. Lumley, S.F., et al., Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N*
309 *Engl J Med*, 2020.
- 310 6. Chau, N.V.V., et al., The natural history and transmission potential of asymptomatic SARS-CoV-2
311 infection. *Clin Infect Dis*, 2020. **71**(10): p. 2679-87.
- 312 7. Allison, J.R., et al., Evaluating aerosol and splatter following dental procedures: Addressing new
313 challenges for oral health care and rehabilitation. *J Oral Rehabil*, 2021. **48**(1): p. 61-72.
- 314 8. Ministry of Housing, Communities, and Local Government. English indices of deprivation 2019. 2019.
- 315 9. Harris, P.A., et al., Research electronic data capture (REDCap)--a metadata-driven methodology and
316 workflow process for providing translational research informatics support. *J Biomed Inform*, 2009. **42**(2): p.
317 377-81.
- 318 10. Cook, A.M., et al., Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to
319 SARS-CoV-2 in mild or moderate non-hospitalised patients. *medRxiv*, 2020: p. 2020.11.30.20229732.
- 320 11. Faustini, S.E., et al., Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and
321 saliva enhances detection of infection. *medRxiv*, 2020: p. 2020.06.16.20133025.
- 322 12. Mattiuzzo, G, et al, *Establishment of the WHO International Standard and Reference Panel for anti-*
323 *SARS-CoV-2 antibody.*, W.H. Organization, Editor. 2020, World Health Organization. p. 60.
- 324 13. Public Health England, *Sero-surveillance of COVID-19*, P.H. England, Editor. 2020.
- 325 14. Wajnberg, A., et al., Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
326 *Science*, 2020. **370**(6521): p. 1227-1230.
- 327 15. Dan, J.M., et al., Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
328 *Science*, 2021. **371**(6529).
- 329 16. Krammer, F., K. Srivastava, and V. Simon, Robust spike antibody responses and increased
330 reactivity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. *medRxiv*,
331 2021: p. 2021.01.29.21250653.
- 332 17. Stamatatos, L., et al., Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination
333 neutralize an emerging variant and SARS-CoV-1. *medRxiv*, 2021: p. 2021.02.05.21251182.
- 334 18. Office of National Statistics, *Coronavirus (COVID-19) Infection Survey, antibody data for the UK: 3*
335 *February 2021*, O.o.N. Statistics, Editor. 2021
- 336

337

338 **Acknowledgements**

339 The authors are grateful to the staff of the University of Birmingham Clinical Immunology Service for
340 facilitating laboratory studies. The authors are also grateful to Joanne Crumpler, Jacqui Rees, Joanne
341 Whitehouse, Joanna Rooney, Amneet Sidhu, Amanda Stokes, Harpreet Dhani, Marie Jones, Kate Ward,
342 Erika Malone, Jessica Chapple and Yvonne Simaloi for their help supporting this study. Finally, the authors
343 are indebted to the DCPs in the West Midlands region who volunteered to participate in this study.

344

345 **Ethical approval**

346 The study was approved by the London - Camden and Kings Cross Research Ethics Committee (reference
347 20/HRA/1817). All participants provided written informed consent prior to enrolment in the study

348

349 **Role of the funding source**

350 The authors are grateful for funding from the Association of Clinical Biochemistry and Laboratory
351 Medicine for supporting this work.

352

353 **Competing interests**

354 MTD reports personal fees from Abingdon Health, outside the submitted work. AMC is an employee of the
355 Binding Site Group. All other authors declare no competing interests.

356

357 **Availability of data and materials**

358 Data are available for a period of 24 months from publication upon reasonable request. Proposals should
359 be directed to the corresponding authors.

360

361 Bibliography

362

363 1. Eyre, D.W., et al., Differential occupational risks to healthcare workers from SARS-CoV-2 observed
364 during a prospective observational study. *Elife*, 2020. **9**.

365 2. Houlihan, C.F., et al., Pandemic peak SARS-CoV-2 infection and seroconversion rates in London
366 frontline health-care workers. *Lancet*, 2020. **396**(10246): p. e6-e7.

367 3. Shields, A., et al., SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare
368 workers: a cross-sectional study. *Thorax*, 2020.

369 4. Hanrath, A.T., B.A.I. Payne, and C.J.A. Duncan, Prior SARS-CoV-2 infection is associated with
370 protection against symptomatic reinfection. *J Infect*, 2020.

371 5. Lumley, S.F., et al., Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care
372 Workers. *N Engl J Med*, 2020.

373 6. Chau, N.V.V., et al., The natural history and transmission potential of asymptomatic SARS-CoV-2
374 infection. *Clin Infect Dis*, 2020. **71**(10): p. 2679-87.

375 7. Allison, J.R., et al., Evaluating aerosol and splatter following dental procedures: Addressing new
376 challenges for oral health care and rehabilitation. *J Oral Rehabil*, 2021. **48**(1): p. 61-72.

377 8. Ministry of Housing, C.a.L.G., English indices of deprivation 2019. 2019.

378 9. Harris, P.A., et al., Research electronic data capture (REDCap)--a metadata-driven methodology
379 and workflow process for providing translational research informatics support. *J Biomed Inform*, 2009.
380 **42**(2): p. 377-81.

381 10. Cook, A.M., et al., Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses
382 to SARS-CoV-2 in mild or moderate non-hospitalised patients. *medRxiv*, 2020: p. 2020.11.30.20229732.

383 11. Faustini, S.E., et al., Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum
384 and saliva enhances detection of infection. *medRxiv*, 2020: p. 2020.06.16.20133025.

385 12. Mattiuzzo, G., Bentley EM, Hassall M, Routley S, Richardson S, Bernasconi V, Kristiansen P,
386 Harvala H, Roberts D, Semple MG, Turtle LCW, Openshaw PJM, Baillie K, ISARIC4C Investigators, Nissen-
387 Meyer L, Branstaeter AB, Baxendale H, Atkinson E, Rigsby P, Padley D, Almond, N, Rose NJ, Page M,
388 *Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody.*, W.H.
389 Organization, Editor. 2020, World Health Organization. p. 60.

390 13. PHE, *Sero-surveillance of COVID-19*, P.H. England, Editor. 2020.

391 14. Wajnberg, A., et al., Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
392 *Science*, 2020. **370**(6521): p. 1227-1230.

393 15. Dan, J.M., et al., Immunological memory to SARS-CoV-2 assessed for up to 8 months after
394 infection. *Science*, 2021. **371**(6529).


395 16. Krammer, F., K. Srivastava, and V. Simon, Robust spike antibody responses and increased
396 reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. *medRxiv*,
397 2021: p. 2021.01.29.21250653.

398 17. Stamatatos, L., et al., Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination
399 neutralize an emerging variant and SARS-CoV-1. *medRxiv*, 2021: p. 2021.02.05.21251182.


400 18. Statistics, O.o.N., *Coronavirus (COVID-19) Infection Survey, antibody data for the UK: 3 February*
401 2021, O.o.N. Statistics, Editor. 2021:

402 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/arti](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveyantibodydatafortheuk/3february2021#collaboration)
403 [cles/coronaviruscovid19infectionsurveyantibodydatafortheuk/3february2021#collaboration](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveyantibodydatafortheuk/3february2021#collaboration).


A



B



C



D




Figure 1: **A** Total anti-SARS-CoV-2 spike glycoprotein antibodies (Total GAM) and IgG and IgA anti SARS-CoV-2 spike glycoprotein antibodies measured at baseline, 3 months and 6 month follow up. At 6 months, only individuals who had not been vaccinated are shown. Data are provided as a ratio of the level of antibody compared to the cutoff calibrator set at 1.0. Percentage of individual above the assay cutoff at each time point is also provided above each column. Median and 95% confidence intervals are shown. **B** Receiver operator characteristic curve describing the relationship between baseline anti SARS-CoV-2 spike glycoprotein IgG ratio and binary IgG seropositivity at 6-month follow up. AUC = 0.80, p=0.01. **C** International reference materials NIBSC 20-136 (WHO) and 20-162 was run in triplicate serial dilutions and the IgG ratio determined. The minimum IgG ratio associated with guaranteed seropositivity 6 months from baseline is shown by the red and blue dotted lines. **D** Kinetics of total antibody response in 423 individuals following a single dose of the Pfizer-BioNTech vaccine. * demonstrate a significant difference (p<0.05) between the distributions of IgGAM ratios at each timepoint following vaccination between individuals who were seropositives and seronegative at baseline as determined by Kolmogorov-Smirnov test. Percentage of individual above the assay cutoff at each time point is also provided.

Table 1: Demographics of study population. Number (%) are presented for categorical and binary characteristics and compared using a Chi-Squared test. Median (interquartile range (IQR)) are presented for continuous characteristics and compared using the Wilcoxon Rank Sum Test.

	All participants n (%)*	Seropositive n (%)*	Seronegative n (%)*	Seroprevalence (%)*	P-value
n	1507 (100)	246 (16.3)	1261 (83.7)	16.3	
Age (years) (median (IQR))	37 (29, 47)	36 (28, 46)	37 (29, 48)	-	0.130
Sex					
Male	371 (24.6)	56 (22.8)	315 (25.0)	15.1	0.461
Female	1136 (75.4)	190 (77.2)	946 (75.0)	16.7	
Ethnicity					
White	830 (55.1)	119 (48.4)	711 (56.4)	14.3	0.020
Asian	584 (38.8)	110 (44.7)	474 (37.6)	18.8	
Black	20 (1.3)	7 (2.9)	13 (1.0)	35.0	
Mixed	39 (2.6)	7 (2.9)	32 (2.5)	18.0	
Other	34 (2.3)	3 (1.2)	31 (2.5)	8.8	
Index of multiple deprivation rank (median (IQR))	11750 (3717, 21688)	8238 (3240,14408)	12081 (3858, 21795)	-	
Diabetic					
Yes	21 (1.4)	4 (1.6)	17 (1.4)	19.1	0.734
No	1486 (98.6)	242 (98.4)	1244 (98.6)	16.3	
Other medical conditions					
Yes	354 (23.3)	55 (22.4)	299 (23.7)	15.5	0.647
No	1153 (76.7)	191 (77.6)	962 (76.3)	16.6	
Smoking					
Never	1100 (73.0)	193 (78.5)	907 (71.9)	17.6	0.007
Former	250 (16.6)	41 (16.7)	206 (16.6)	16.4	
Current	157 (10.4)	12 (4.9)	145 (11.5)	7.6	
Occupation					
Dentist	687 (45.6)	115 (46.8)	572 (45.4)	16.7	0.398
Dental nurse	528 (35.0)	89 (36.2)	439 (34.8)	16.9	
Dental hygienist/therapist	116 (7.7)	18 (7.3)	98 (7.7)	15.5	
Receptionist	80 (5.3)	5 (2.0)	75 (6.0)	6.3	
Clinical dental technician	2 (0.1)	0 (0.0)	2 (0.2)	0.0	
Practice manager	51 (3.4)	11 (4.5)	40 (3.2)	21.6	
Other dental healthcare occupation	22 (1.5)	5 (2.0)	17 (1.4)	22.7	
Auxiliary staff in dental practice/hospital/clinic	13 (0.9)	2 (0.8)	11 (0.9)	15.4	
Other (no detail provided)	8 (0.5)	1 (0.4)	7 (0.6)	12.5	

*unless otherwise stated